Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | NMBR | P28336 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7449299 | 0.93 | CA1 (0.43) | MMP3PSMB1CA1NMBRCA5A | |
| SCHEMBL2582313 | 0.73 | TP53 (0.37) | PSMB5 | |
| SCHEMBL2576523 | 0.72 | PSMB1 (0.52) | PSMB1CTSLCTSB | |
| SCHEMBL2585850 | 0.68 | SPPL2A (0.57) | PSMB1CTSL | |
| SCHEMBL6671871 | 0.67 | CTSS (0.55) | PSMB1CTSKCTSSCTSLCTSB | |
| SCHEMBL8493861 | 0.67 | CTSS (0.55) | PSMB1CTSKCTSSCTSLCTSB | |
| SCHEMBL18735868 | 0.67 | PSMB1 (0.56) | PSMB1CTSKCTSSCTSLCTSB | |
| SCHEMBL13673908 | 0.66 | ADORA3 (0.50) | MMP3PSMB1CTSKCTSLCTSB | |
| SCHEMBL27429302 | 0.66 | PSMB1 (0.67) | MMP3PSMB1CTSKCTSSCTSL | |
| SCHEMBL19015747 | 0.66 | MMP9 (0.62) | PSMB1CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | VAZQUEZ MICHAEL L (US) | 2002-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | MMP3 397/4885PSMB1 116/4885CA1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.